Citations (18)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
David Conde-Estévez, Iván Henríquez, Jesús Muñoz-Rodríguez & Alejo Rodriguez-Vida. (2022) Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions. Expert Opinion on Drug Metabolism & Toxicology 18:9, pages 601-613.
Read now
Read now
Vicente Escudero-Vilaplana, Roberto Collado-Borrell, Angela Hoyo-Muñoz, Alvaro Gimenez-Manzorro, Antonio Calles, Santiago Osorio, Ana Herranz-Alonso & Maria Sanjurjo-Sáez. (2020) Potential drug interactions between targeted oral antineoplastic agents and concomitant medication in clinical practice. Expert Opinion on Drug Safety 19:8, pages 1041-1048.
Read now
Read now
Almudena Ribed, Vicente Escudero-Vilaplana, Rosa Maria Romero-Jimenez, Irene Iglesias-Peinado, Ana Herranz-Alonso & Maria Sanjurjo-Saez. (2016) Guiding pharmacist clinical interviews: a safety tool to support the education of patients treated with oral antineoplastic agents. Expert Opinion on Drug Safety 15:4, pages 427-435.
Read now
Read now
Articles from other publishers (15)
Fauziya, Akash Gupta, Arif Nadaf, Shadaan Ahmad, Nazeer Hasan, Mohammad Imran, Amirhossein Sahebkar, Gaurav Kumar Jain, Prashant Kesharwani & Farhan J. Ahmad. (2023) Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies. Medical Oncology 40:6.
Crossref
Crossref
S. Le Tohic, F. Darbon, C. Paysant & E. Fougereau. (2023) Contribution du dossier pharmaceutique dans l’analyse des interactions médicamenteuses lors de la rétrocession dans un centre de lutte contre le cancer. Annales Pharmaceutiques Françaises 81:2, pages 334-345.
Crossref
Crossref
Craig J. Beavers, Jo E. Rodgers, Aaron J. Bagnola, Theresa M. Beckie, Umberto Campia, Katherine E. Di Palo, Tochi M. Okwuosa, Eugene R. Przespolewski & Susan Dent. (2022) Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association. Circulation 145:15.
Crossref
Crossref
Metin Deniz KARAKOÇ. (2022) Kanser Hastalarında Polifarmasi ve İlaç EtkileşimleriPolypharmacy and Drug Interactions in Cancer Patients. Adnan Menderes Üniversitesi Sağlık Bilimleri Fakültesi Dergisi 6:1, pages 31-42.
Crossref
Crossref
Katja Schlichtig, Pauline Dürr, Frank Dörje & Martin F. Fromm. (2021) Medication Errors During Treatment with New Oral Anticancer Agents: Consequences for Clinical Practice Based on the AMBORA Study. Clinical Pharmacology & Therapeutics 110:4, pages 1075-1086.
Crossref
Crossref
Gisela Riu-Viladoms, Esther Carcelero San Martín, M. Teresa Martín-Conde & Natàlia Creus. (2019) Drug interactions with oral antineoplastic drugs: The role of the pharmacist. European Journal of Cancer Care 28:1, pages e12944.
Crossref
Crossref
Joana D. Campeiro, Marcelo P. Marinovic, Fernando Cintra Carapeto, Caroline Dal Mas, Gabriela Guilherme Monte, Lucas Carvalho Porta, Marcela B. Nering, Eduardo B. Oliveira & Mirian A. F. Hayashi. (2017) Oral treatment with a rattlesnake native polypeptide crotamine efficiently inhibits the tumor growth with no potential toxicity for the host animal and with suggestive positive effects on animal metabolic profile. Amino Acids 50:2, pages 267-278.
Crossref
Crossref
Caroline Gay, Delphine Toulet & Pascal Le Corre. (2017) Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy. Hematological Oncology 35:3, pages 259-280.
Crossref
Crossref
D. Conde-Estévez. (2016) Targeted cancer therapy: interactions with other medicines. Clinical and Translational Oncology 19:1, pages 21-30.
Crossref
Crossref
Sara L. Henderson, Wendy A. Teft & Richard B. Kim. (2016) Profound reduction in tamoxifen active metabolite endoxifen in a breast cancer patient treated with rifampin prior to initiation of an anti-TNFα biologic for ulcerative colitis: a case report. BMC Cancer 16:1.
Crossref
Crossref
Roberto Collado-Borrell, Vicente Escudero-Vilaplana, Rosa Romero-Jiménez, Irene Iglesias-Peinado, Ana Herranz-Alonso & María Sanjurjo-Sáez. (2016) Oral antineoplastic agent interactions with medicinal plants and food: an issue to take into account. Journal of Cancer Research and Clinical Oncology 142:11, pages 2319-2330.
Crossref
Crossref
Rehana Jamani, Esther K. Lee, Scott R. Berry, Ronak Saluja, Carlo DeAngelis, Angie Giotis & Urban Emmenegger. (2016) High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate. European Journal of Clinical Pharmacology 72:11, pages 1391-1399.
Crossref
Crossref
D. Conde-Estévez, D. Echeverría-Esnal, I. Tusquets & J. Albanell. (2015) Potential clinical relevant drug–drug interactions: comparison between different compendia, do we have a validated method?. Annals of Oncology 26:6, pages 1272.
Crossref
Crossref
Christopher J.A. Cowie & Mark O. Cunningham. (2014) Peritumoral epilepsy: Relating form and function for surgical success. Epilepsy & Behavior 38, pages 53-61.
Crossref
Crossref
Solange Peters, Stefan Zimmermann & Alex A. Adjei. (2014) Oral epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: Comparative pharmacokinetics and drug–drug interactions. Cancer Treatment Reviews 40:8, pages 917-926.
Crossref
Crossref